Cargando…

Complete Cerebrospinal Fluid Response to T-DM1 in HER2 Positive Metastatic Breast Cancer: A Case Report

Leptomeningeal carcinomatosis is a rare but serious consequence of pre-existing tumors, such as breast, lung, and gastrointestinal carcinomas. Further, leptomeningeal carcinomatosis is more frequently diagnosed with breast cancers, if only because breast cancers are diagnosed far more often than any...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zacchi, Francesca, Giontella, Elena, Nottegar, Alessia, Fiorio, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051149/ https://www.ncbi.nlm.nih.gov/pubmed/36983911 http://dx.doi.org/10.3390/life13030756

Ejemplares similares

Dramatic Response to Pyrotinib and T-DM1 in HER2-Negative Metastatic Breast Cancer With 2 Activating HER2 Mutations
por: Tian, Hao, et al.
Publicado: (2023)

Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases
por: Siravegna, Giulia, et al.
Publicado: (2017)

Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid
por: De Mattos-Arruda, Leticia
Publicado: (2017)

Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
por: Ma, Bo, et al.
Publicado: (2016)

Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
por: Hunter, Francis W., et al.
Publicado: (2019)

Novel Anti-HER2 Antibody-Drug Conjugates Versus T-DM1 for HER2-Positive Metastatic Breast Cancer After Tyrosine Kinase Inhibitors Treatment
por: Ji, Chenchen, et al.
Publicado: (2023)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
por: Sanglier, Thibaut, et al.
Publicado: (2022)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
por: Omarini, Claudia, et al.
Publicado: (2022)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Phase 1b/2a study of trastuzumab emtansine (T-DM1), paclitaxel, and pertuzumab in HER2-positive metastatic breast cancer
por: Krop, Ian E., et al.
Publicado: (2016)

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
por: Abraham, Jame, et al.
Publicado: (2019)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer
por: Malani, Rachna, et al.
Publicado: (2020)

Safety and efficacy of the addition of pertuzumab to T-DM1 ± taxane in patients with HER2-positive, locally advanced or metastatic breast cancer: a pooled analysis
por: Zhang, Jing, et al.
Publicado: (2017)

ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
por: Griguolo, Gaia, et al.
Publicado: (2020)

Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
por: Denduluri, Neelima, et al.
Publicado: (2022)

Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
por: Allegretti, Matteo, et al.
Publicado: (2021)

Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
por: Lu, Dan, et al.
Publicado: (2014)

The antitumor immune response in HER-2 positive, metastatic breast cancer patients
por: Juranic, Zorica D, et al.
Publicado: (2005)

Efficacy and safety of trastuzumab emtansine (T-DM1) in the treatment of HER2-positive metastatic breast cancer (MBC): a meta-analysis of randomized controlled trial
por: Yan, Hongjing, et al.
Publicado: (2017)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
por: Bon, Giulia, et al.
Publicado: (2020)

STAT3 activation confers trastuzumab‐emtansine (T‐DM1) resistance in HER2‐positive breast cancer
por: Wang, Lei, et al.
Publicado: (2018)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
por: Liu, Peipei, et al.
Publicado: (2020)

Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells
por: Endo, Yukinori, et al.
Publicado: (2021)

Reviving immunogenic cell death upon targeting TACC3 enhances T-DM1 response in HER2-positive breast cancer
por: Gedik, Mustafa Emre, et al.
Publicado: (2023)

HER2 expression and efficacy of T-DM1
por: Montemurro, Filippo
Publicado: (2014)

Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature
por: Borges, Giuliano Santos, et al.
Publicado: (2015)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
por: Olson, Devra, et al.
Publicado: (2023)

Predictors of pathological complete response to neoadjuvant treatment and changes to post-neoadjuvant HER2 status in HER2-positive invasive breast cancer
por: Katayama, Ayaka, et al.
Publicado: (2021)

Complete pathologic response of HER2-positive breast cancer liver metastasis with dual Anti-HER2 antagonism
por: Schoellhammer, Hans F, et al.
Publicado: (2014)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study
por: Schettini, F., et al.
Publicado: (2021)

Longitudinal pathways of cerebrospinal fluid and positron emission tomography biomarkers of amyloid-β positivity
por: Sala, Arianna, et al.
Publicado: (2020)

Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer
por: Zhang, Hang, et al.
Publicado: (2017)

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer
por: Rinnerthaler, Gabriel, et al.
Publicado: (2019)

Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1)
por: Chung, Yuan-Chiang, et al.
Publicado: (2015)

Dual endothelin receptor inhibition enhances T-DM1 efficacy in brain metastases from HER2-positive breast cancer
por: Askoxylakis, Vasileios, et al.
Publicado: (2019)

The EMA review of trastuzumab emtansine (T-DM1) for the adjuvant treatment of adult patients with HER2-positive early breast cancer
por: Delgado, J., et al.
Publicado: (2021)

Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ult3r517m3ed95p6ecvbgd4qnf